MYPROSTATESCORE 2.0
Clear Results. Confident Decision.
MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing a comprehensive array of 18 unique gene transcripts. Our algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility, allowing MPS2 to be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference. Receive individualized reports with results tailored to unique patient and clinical context.
Stay Up To Date
Resources
Industry news, men’s health information, and expert prostate cancer and risk assessment research.
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
Lynx Dx's Biomarker Test Offers Market-Leading Accuracy in Prostate [...]
Revealing the Latest Prostate Cancer Insights and Innovation at AUA2024!
MyProstateScore 2.0 (MPS2) is the only biomarker test with 99% [...]
A Brief Glossary of Terms Related to Prostate Cancer
Prostate cancer awareness is key for men’s health. Get comfortable with terms like “biopsy,” “PSA,” “clinically significant” and “grade group.”